Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the lipid disorder treatment market grown over the years?

The market for lipid disorder treatment has seen swift expansion in the past years. Its growth is predicted to rise from $10.69 billion in 2024 to $12.09 billion in 2025, with a compounded annual growth rate (CAGR) of 13.2%. The historic period’s growth can be linked to a surge in the adoption of a sedentary lifestyle, an increase in the working population, heightened awareness about the disease and its treatments, an increase in desk jobs, and a rise in the incidence of familial combined hyperlipidemia.

What Is the forecasted market size and growth rate for the lipid disorder treatment market?

The market size of lipid disorder treatment is forecasted to experience significant expansion in the coming years, with an anticipated rise to $19.56 billion in 2029, marking a compound annual growth rate (CAGR) of 12.8%. The expected growth during the forecast period can be linked to the escalating incidences of obesity and high cholesterol, the rising prevalence of cardiovascular diseases, an increase in cases of heart diseases brought about by high cholesterol, as well as the growing demand for effective and safe treatments, spurred by excessive alcohol intake and smoking. Key trends for the forecast period are improvements in drug development technology, product innovation, expansion of investments in business growth, technological progress in treatment facilities and clinical advancements.

Get your lipid disorder treatment market report here!

https://www.thebusinessresearchcompany.com/report/lipid-disorder-treatment-global-market-report

What are the major factors driving growth in the lipid disorder treatment market?

The escalating incidents of obesity and heightened cholesterol levels are anticipated to fuel the expansion of the lipid disorder treatment market. Obesity, marked by an overaccumulation of body fat, along with high cholesterol, which indicates increased levels of cholesterol in the bloodstream, both pose considerable health hazards. These issues are becoming more prevalent due to poor dietary habits, inactive lifestyles, genetic predisposition, and external environmental factors. Treating lipid disorders serves as a key component in managing obesity and high cholesterol, integrating medication therapies with lifestyle adjustments, weight control tactics, patient teaching, and comprehensive care. For example, the World Obesity Atlas 2022, released by the World Obesity Federation, a non-profit organization based in the UK, forecasted in May 2022, that by 2030, one billion people worldwide, including one in every five women and one in every seven men, will be dealing with obesity, and this number is expected to rise to four billion people, or 51% of the global population, by 2035. Thus, escalating incidents of obesity and high cholesterol are pushing the growth path of the lipid disorder treatment market.

What key areas define the segmentation of the global lipid disorder treatment Market?

The lipid disorder treatment market covered in this report is segmented –

1) By Drug Type: Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin, Pravastatin, Other Drugs

2) By Indication: Familial Combined Hyperlipidemia, Familial Defective Apolipoprotein B-100, Familial Dysbetalipoproteinemia, Familial Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia, Other Indications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Atorvastatin: Generic Atorvastatin, Brand-Name Atorvastatin ( Lipitor)

2) By Fluvastatin: Generic Fluvastatin, Brand-Name Fluvastatin ( Lescol)

3) By Rosuvastatin: Generic Rosuvastatin, Brand-Name Rosuvastatin ( Crestor)

4) By Simvastatin: Generic Simvastatin, Brand-Name Simvastatin ( Zocor)

5) By Pravastatin: Generic Pravastatin, Brand-Name Pravastatin ( Pravachol)

6) By Other Drugs: Ezetimibe, Pcsk9 Inhibitors ( Alirocumab, Evolocumab), Fibrates ( Gemfibrozil, Fenofibrate), Niacin (Vitamin B3), Omega-3 Fatty Acids ( Icosapent Ethyl)

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15600&type=smp

What are the top market players propelling the growth of the lipid disorder treatment industry?

Major companies operating in the lipid disorder treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca Plc, Fresenius SE & Co. KGaA, Abbott Laboratories Inc., Novartis AG, GlaxoSmithKline Plc, Wockhardt Ltd., Eli Lilly and Company, Amgen Inc., Boehringer-Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Kaneka Corporation, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Emcure Pharmaceuticals Limited, Kowa Pharmaceuticals America Inc., Concord Biotech Limited, Biocon Ltd., Ranbaxy Laboratories Limited

How are evolving market trends shaping lipid disorder treatment Strategies?

Key players in the lipid disorder treatment market are focusing on the creation of proprotein convertase subtilisin type 9 (PCSK9) inhibitors, responding to the demand for more advanced and specific treatments for high cholesterol levels. PCSK9 inhibitors work to manage lipid disorders by improving the evacuation of LDL cholesterol from the bloodstream, in turn lowering the likelihood of cardiovascular incidents in patients at high risk. For instance, Regeneron Pharmaceuticals Inc., a biotechnology firm based in the US, obtained approval in March 2024 for the use of Praluent (alirocumab) injection from the U.S. Food and Drug Administration (FDA) for the treatment of heterozygous familial hypercholesterolemia (HeFH) in children aged 8 and above. Praluent injection stands out due to its ability to prevent PCSK9 from binding to the LDL receptor, thus increasing the number of LDL receptors on the surface of liver cells, facilitating the removal of LDL and lowering LDL-C levels in the bloodstream.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15600

What regions are dominating the lipid disorder treatment market growth?

North America was the largest region in the lipid disorder treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lipid disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Hypolipidemics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hypolipidemics-global-market-report

Hyperlipidemia Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report

Lecithin And Phospholipids Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/lecithin-and-phospholipids-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: